These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 8142357)

  • 1. Conformational analysis of two cyclic analogs of angiotensin: implications for the biologically active conformation.
    Nikiforovich GV; Kao JL; Plucinska K; Zhang WJ; Marshall GR
    Biochemistry; 1994 Mar; 33(12):3591-8. PubMed ID: 8142357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel cyclic analogs of angiotensin II with cyclization between positions 5 and 7: conformational and biological implications.
    Zhang WJ; Nikiforovich GV; Pérodin J; Richard DE; Escher E; Marshall GR
    J Med Chem; 1996 Jul; 39(14):2738-44. PubMed ID: 8709104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-dimensional recognition requirements for angiotensin agonists: a novel solution for an old problem.
    Nikiforovich GV; Marshall GR
    Biochem Biophys Res Commun; 1993 Aug; 195(1):222-8. PubMed ID: 8363604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The design and synthesis of a potent Angiotensin II cyclic analogue confirms the ring cluster receptor conformation of the hormone Angiotensin II.
    Matsoukas JM; Polevaya L; Ancans J; Mavromoustakos T; Kolocouris A; Roumelioti P; Vlahakos DV; Yamdagni R; Wu Q; Moore GJ
    Bioorg Med Chem; 2000 Jan; 8(1):1-10. PubMed ID: 10968258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proposals for the angiotensin II receptor-bound conformation by comparative computer modeling of AII and cyclic analogs.
    Joseph MP; Maigret B; Scheraga HA
    Int J Pept Protein Res; 1995 Dec; 46(6):514-26. PubMed ID: 8748712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple binding modes for the receptor-bound conformations of cyclic AII agonists.
    Plucinska K; Kataoka T; Yodo M; Cody WL; He JX; Humblet C; Lu GH; Lunney E; Major TC; Panek RL
    J Med Chem; 1993 Jun; 36(13):1902-13. PubMed ID: 8515427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin II vs its type I antagonists: conformational requirements for receptor binding assessed from NMR spectroscopic and receptor docking experiments.
    Wilkes BC; Masaro L; Schiller PW; Carpenter KA
    J Med Chem; 2002 Sep; 45(20):4410-8. PubMed ID: 12238921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the molecular basis of the recognition of angiotensin II (AII). NMR structure of AII in solution compared with the X-ray structure of AII bound to the mAb Fab131.
    Tzakos AG; Bonvin AM; Troganis A; Cordopatis P; Amzel ML; Gerothanassis IP; van Nuland NA
    Eur J Biochem; 2003 Mar; 270(5):849-60. PubMed ID: 12603318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solution conformations of the peptide backbone for DPDPE and its beta-MePhe4-substituted analogs.
    Nikiforovich GV; Prakash OM; Gehrig CA; Hruby VJ
    Int J Pept Protein Res; 1993 Apr; 41(4):347-61. PubMed ID: 8496017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The utility of side-chain cyclization in determining the receptor-bound conformation of peptides: cyclic tripeptides and angiotensin II.
    Kataoka T; Beusen DD; Clark JD; Yodo M; Marshall GR
    Biopolymers; 1992 Nov; 32(11):1519-33. PubMed ID: 1333831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solution conformations of two flexible cyclic pentapeptides: cyclo(Gly-Pro-D-Phe-Gly-Ala) and cyclo(Gly-Pro-D-Phe-Gly-Val).
    Stroup AN; Rockwell AL; Gierasch LM
    Biopolymers; 1992 Dec; 32(12):1713-25. PubMed ID: 1472654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined use of molecular dynamics simulations and NMR to explore peptide bond isomerization and multiple intramolecular hydrogen-bonding possibilities in a cyclic pentapeptide, cyclo(Gly-Pro-D-Phe-Gly-Val).
    Liu ZP; Gierasch LM
    Biopolymers; 1992 Dec; 32(12):1727-39. PubMed ID: 1472655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural features of angiotensin II which are important for biologic activity.
    Peach MJ
    Kidney Int Suppl; 1979 Mar; (9):S3-6. PubMed ID: 289861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The octapeptide angiotensin II adopts a well-defined structure in a phospholipid environment.
    Carpenter KA; Wilkes BC; Schiller PW
    Eur J Biochem; 1998 Jan; 251(1-2):448-53. PubMed ID: 9492317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conformational analysis of beta-methyl-para-nitrophenylalanine stereoisomers of cyclo[D-Pen2, D-Pen5]enkephalin by NMR spectroscopy and conformational energy calculations.
    Shenderovich MD; Kövér KE; Nikiforovich GV; Jiao D; Hruby VJ
    Biopolymers; 1996 Feb; 38(2):141-56. PubMed ID: 8589249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the structural basis of the hypertensive properties of angiotensin II: a solved mystery or a controversial issue?
    Tzakos AG; Gerothanassis IP; Troganis AN
    Curr Top Med Chem; 2004; 4(4):431-44. PubMed ID: 14965310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An investigation of angiotensin II agonist and antagonist analogues with 5,5-dimethylthiazolidine-4-carboxylic acid and other constrained amino acids.
    Samanen J; Cash T; Narindray D; Brandeis E; Adams W; Weideman H; Yellin T; Regoli D
    J Med Chem; 1991 Oct; 34(10):3036-43. PubMed ID: 1920354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Solvent effects on the conformation of cyclo(-D-Trp-D-Asp-Pro-D-Val-Leu-). An NMR spectroscopy and molecular modeling study.
    Gonnella NC; Zhang X; Jin Y; Prakash O; Paris CG; Kolossváry I; Guida WC; Bohacek RS; Vlattas I; Sytwu T
    Int J Pept Protein Res; 1994 May; 43(5):454-62. PubMed ID: 8070969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and biological activities of four angiotensin II receptor ligands with gamma-turn mimetics replacing amino acid residues 3-5.
    Schmidt B; Lindman S; Tong W; Lindeberg G; Gogoll A; Lai Z; Thörnwall M; Synnergren B; Nilsson A; Welch CJ; Sohtell M; Westerlund C; Nyberg F; Karlén A; Hallberg A
    J Med Chem; 1997 Mar; 40(6):903-19. PubMed ID: 9083479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An effort to understand the molecular basis of hypertension through the study of conformational analysis of losartan and sarmesin using a combination of nuclear magnetic resonance spectroscopy and theoretical calculations.
    Mavromoustakos T; Kolocouris A; Zervou M; Roumelioti P; Matsoukas J; Weisemann R
    J Med Chem; 1999 May; 42(10):1714-22. PubMed ID: 10346924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.